Emyria has announced an agreement with one of Australia’s leading pharmaceutical companies, Aspen Australia, to support the registration & commercialisation of EMD-RX5 as an over-the-counter treatment in Australia.

Currently in Phase 3 Clinical Trials, EMD-RX5 is a capsule-form medication aimed at treating mild anxiety & stress for patients with a chronic health condition.

Read more about the agreement: http://ow.ly/MCQS50Nznx2